Proportion of Participants With Type 2 Diabetes Achieving a Metabolic Composite Endpoint With Once-Weekly Semaglutide Treatment vs Comparators
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China
Diabetes Obes Metab 2023 Oct 12;[EPub Ahead of Print], L Ji, AJ Ahmann, B Ahrén, MS Capehorn, P Hu, I Lingvay, W Liu, HW Rodbard, Z Shen, C SorliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.